Investigating gray matter damage in primary progressive multiple sclerosis using advanced MRI

Investigating Cortical Gray Matter Demyelination in Primary Progressive Multiple Sclerosis at 7 Tesla

Observational Danish Research Centre for Magnetic Resonance · NCT04977622

This study is trying to see how gray matter damage affects people with primary progressive multiple sclerosis by using advanced MRI technology to look for signs of brain injury and its link to physical and mental challenges.

Quick facts

Study typeObservational
Enrollment60 (estimated)
Ages18 Years to 80 Years
SexAll
SponsorDanish Research Centre for Magnetic Resonance Academic / other
Locations1 site (Hvidovre)
Trial IDNCT04977622 on ClinicalTrials.gov

What this trial studies

This observational study aims to explore the role of gray matter in primary progressive multiple sclerosis (PPMS) using ultra-high field 7 Tesla magnetic resonance imaging (MRI). It will assess the distribution and characteristics of cortical lesions and their relationship to physical and cognitive impairments in PPMS patients. By enrolling 30 individuals diagnosed with PPMS, the study seeks to identify both visible and invisible features of cortical damage that contribute to disease progression. The findings could lead to the development of biomarkers for monitoring and understanding PPMS.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals diagnosed with primary progressive multiple sclerosis who have an Expanded Disability Status Scale score of 6.5 or lower.

Not a fit: Patients with relapsing forms of multiple sclerosis or those with contraindications to MRI will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide critical insights into the mechanisms of progression in PPMS, potentially leading to improved diagnostic and therapeutic strategies.

How similar studies have performed: While studies using standard MRI techniques have been conducted, the use of 7 Tesla MRI for investigating cortical gray matter in PPMS is a novel approach that has not been widely explored.

Eligibility criteria

Show full inclusion / exclusion criteria
PATIENTS

Inclusion Criteria:

* Diagnosed with primary progressive multiple sclerosis
* Expanded Disability Status Scale of ≤ 6.5
* No clinical relapse within last three months
* Have the ability to comply with all requirements of the study protocol, as determined by the investigator

Exclusion Criteria:

* Pregnancy
* Pacemaker or other implanted electronic devices
* Claustrophobia
* Psychiatric disorder
* Administration of acute cortisol
* Changes in pharmacological treatment within the last 3 months
* Any contraindication to MRI
* Persons who do not wish to be informed about abnormal findings as part of the investigations

HEALTHY CONTROLS

Inclusion Criteria:

* Able bodied
* Have the ability to comply with all requirements of the study protocol, as determined by the investigator

Exclusion Criteria:

* Pregnancy
* Under medication at the time of the experiment (with the exception of contraceptive drugs)
* History of neurologic disease
* Pacemaker or other implanted electronic devices
* History of cerebral hemorrhage or brain damage
* Claustrophobia
* Psychiatric disorder
* Any contraindication to MRI
* Persons who do not wish to be informed about abnormal findings as part of the investigations

Where this trial is running

Hvidovre

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Primary Progressive Multiple SclerosisMagnetic Resonance ImagingUltra-high field MRICortexMultiple SclerosisSensorimotor FunctionMyelin7T
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.